Doubling Down

Following up on our recent white paper, Biopharma’s COVID Capital Comeback, here is a look at the greatest risk facing public biopharma companies — single asset failures — and what they can do during this time of robust capital.

We are excited to share our newest white paper: Doubling Down: The Power of Asset Diversification in a Time of Robust Capital.

In an environment of positive stock momentum and low cost capital, public biotech teams would be well-served to raise more money or use their inflated stock price to diversify their portfolios in the event of a single product failure. Considering single product failures are a regular occurrence — and if you’re going to make an investment — why not protect your company by diversifying your portfolio while the cost of capital is low?